EP Patent

EP2563117A1 — Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males

Assigned to Salix Pharmaceuticals Ltd · Expires 2013-03-06 · 13y expired

What this patent protects

The instant application provides methods and compositions for the treatment of male subjects having ulcerative colitis.

USPTO Abstract

The instant application provides methods and compositions for the treatment of male subjects having ulcerative colitis.

Drugs covered by this patent

balsalazide-disodium (BALSALAZIDE DISODIUM)

Patent Metadata

Patent number: EP2563117A1
Jurisdiction: EP
Classification: —
Expires: 2013-03-06
Drug substance claim: No
Drug product claim: No
Assignee: Salix Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.